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Summary
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Background: Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are the first-
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line treatment agents for chronic hepatitis B virus (HBV). Recently, whether the de-
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TDF has been debated. We compared the incidence of HCC among treatment-naïve
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and a minimum of 12 months of prior enrolment, of whom 3934 and 6127 initiated

gree to which the risk of hepatocellular carcinoma (HCC) may be reduced by ETV vs
patients receiving TDF vs ETV in the United States.
Methods: From a large administrative medical claims database of commercially insured patients, we identified 166,933 adults with a diagnosis of chronic hepatitis B
ETV and TDF respectively. Fine-Gray hazard regression models incorporating treatment propensity scores (PS) were used to estimate the risk of HCC incidence associated with TDF vs ETV; variables considered for adjustment included demographic
characteristics, concomitant medication use and baseline comorbidities, as well as
competing events including liver transplantation and medication changes.
Results: After PS weighting, the TDF and ETV groups were well-matched. During the
follow-up, 90 patients developed HCC, including 50 receiving ETV and 40 receiving
TDF, giving rise to crude incidence rates of 0.62 per 100 person-years (PY) and 0.30
per 100 PY respectively. In PS-weighted, multivariable analysis, TDF was associated
with a subdistribution hazard ratio for HCC of 0.58 (95% confidence interval [CI]:
0.38–0.89) compared to ETV. Results were similar when patients ≥40 years and men
and women were analysed separately.
Conclusion: Among commercially insured, treatment-naïve patients with chronic
hepatitis B in the United States, treatment with TDF was associated with significantly
lower risk of HCC than ETV.
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Classification of Diseases (ICD) codes. For this analysis, submitted
claims from 1 January 2006 through 30 March 2019 were used.

Hepatitis B virus (HBV) is a group 1 human carcinogen as designated

Because all data are de-identified, this study was considered exempt

by the International Agency for Research on Cancer.1 Globally, more

from institutional review board oversight.

than 50% of hepatocellular carcinoma (HCC) is attributable to HBV
2

This study employs a retrospective cohort design in which the

infection. Of the estimated 250 million individuals with chronic HBV

exposure (ie use of anti-viral agents) was recorded before the out-

infection, approximately 325,000 succumb to HCC each year.3–5

come (ie occurrence of HCC). From the data set, we assembled a

With the advent of effective oral nucleoside/nucleotide ana-

cohort of adults (≥18 years) with chronic hepatitis B, from which we

logue polymerase reverse transcriptase inhibitors such as entecavir

identified patients newly initiating ETV or TDF treatment. The indi-

(ETV) and tenofovir disoproxil fumarate (TDF) in the 2000s, effec-

vidual administrative codes for these and other inclusion and exclu-

tive viral suppression, achievable in the majority of patients, has

sion criteria, as well as the outcome of HCC, are listed in Table S1. To

been associated with reduced risk of HCC.6–8 Although randomised

maximise the likelihood that patients were treatment naïve and were

clinical trial data are limited to one study which demonstrated that

at risk for incident HCC, we required a minimum of 1 year of enrol-

lamivudine, compared to placebo, was associated with lower inci-

ment prior to the index diagnosis. This look back period was used

dence of HCC among patients with active viral replication and ad-

to ascertain the absence of prior HCC, comorbidities and of prior

vanced fibrosis, a multitude of observational and modelling studies

anti-HBV medications use. Exclusion criteria included: evidence of

have suggested significant reductions in HCC risk in patients receiv-

co-infection with HIV, hepatitis C virus (HCV) or hepatitis D virus

7,9–13

Anti-viral therapy may reduce

(HDV); absence of treatment with ETV or TDF; simultaneous expo-

the risk of HCC by a number of mechanisms such as abrogation of

sure to ETV and TDF; and prior exposure to pegylated interferon

inflammation-mediated signalling, prevention or regression of fibro-

alpha, lamivudine, adefovir dipivoxil or telbivudine. In addition, to

sis altering the microenvironment in the liver and improvement in

exclude potential prevalent HCC at baseline, patients with a diag-

ing effective anti-viral therapy.

14–19

nosis of HCC, receipt of chemotherapy or liver transplant prior to or

immune response.

In most advanced healthcare settings, the majority of patients

within 6 months after treatment initiation were excluded from the

being treated for chronic HBV infection receive long-term anti-viral

study. We employed a broad definition of HCC in order to capture all

therapy and achieve sustained suppression of viral activity and clin-

cases based on an assumption that malignant liver lesions occurring

ical remission. Thus, in patients with compensated liver disease re-

in patients being treated with anti-HBV medications are highly likely

ceiving modern anti-viral therapy, HBV’s impact on morbidity and

to be HCC. In addition, we assessed the validity of this assumption

mortality associated with cirrhosis and liver failure may essentially

by a sensitivity analysis using a narrower case definition.

be eliminated, highlighting HCC as the key determinant of long term
20

Included patients were followed from initiation of ETV or TDF

Although ETV and TDF are thought to

to the first of the following events: (1) HCC diagnosis, (2) end of

share similar anti-viral potency, findings from several recent reports

insurance enrolment or (3) 30 March 2019, the last day covered by

suggest that patients receiving TDF may experience lower HCC in-

the data set. Initiation of a new anti-viral therapy, breaks in anti-

cidence than those receiving ETV.7,21–24 Meanwhile, other studies,

viral treatment >90 days, and liver transplantation were recognised

notably those in Western countries, have not observed a significant

as potential competing events. Figure 1 summarises the cohort

difference in HCC risk. 25–29 Thus, whether the choice of HBV treat-

definition and determination of person-time. Unadjusted incidence

ment has a clinically meaningful impact on subsequent HCC risk has

rates of HCC in each treatment group were calculated as number

been debated. In this work, using a large US administrative claims

of events per 100 person-years with exact Poisson 95% confi-

database, we sought to compare the risk of incident HCC among pa-

dence intervals (CIs). Graphic representation of the time to HCC

tients with chronic hepatitis B starting treatment with ETV vs TDF.

development was generated using Kaplan–Meier methods. The risk

outcome in those patients.

of HCC development associated with TDF vs ETV was estimated

2 | M E TH O DS

using Fine-G ray subdistribution hazard competing risks methods.
An array of covariates was considered for adjustment including age,
sex, calendar year of TDF or ETV initiation, and health conditions

The data set used for this analysis is the IQVIA PharMetrics Plus™

and medications claimed on or before baseline. Inverse probability

administrative claims database. It is the largest, non-payer–owned,

of treatment weighing (IPTW) with stabilised propensity score (PS)

integrated claims database of commercial insurers (thus, exclusive

weights was used to balance the baseline covariates between the

of public payers, such as Medicare) in the United States, consisting

TDF and ETV cohorts. Liver disease variables and variables asso-

of adjudicated medical and pharmacy claims for over 150 million US

ciated with HCC risk at P < 0.10 in univariate logistic regression

health plan enrolees since 2006. Designed to be representative of

models were included in the PS estimation (Table S2). Effectiveness

the US commercially insured population, it covers both inpatient and

of the IPTW procedure in balancing baseline characteristics was

outpatient claims as well as retail and mail order pharmacy claims.

assessed by examining the standardised differences of covariates

Dispensed medications are recorded based on generic product iden-

between the cohorts 30; no standardised differences over 10% were

tifier codes, while diagnoses are recorded based on International

observed.
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Although the approved indications for ETV are TDF are similar,
only TDF is used for treatment of HBV-infected pregnant women to

3

infarction (AMI) and emphysema, outcome states implausibly related
to treatment using ETV or TDF.

reduce mother-to-child transmission. This subgroup of TDF-treated
patients is expected to be at low absolute risk of HCC and thus may
potentially skew the results of the analysis. To address this potential

3 | R E S U LT S

concern, and because pregnancy is not captured reliably in administrative claims data, we performed sensitivity analyses restricting

In the data set, we identified 166 933 patients with evidence of

to the following subgroups: (1) patients over 40 years of age and

HBV infection, of whom 10 061 met the eligibility criteria, including

(2) men and women separately. Lastly, to check for residual bias

3934 receiving ETV and 6127 TDF (Figure 2). In Table 1, patients

resulting from unmeasured confounding, we repeated the analy-

were most commonly in their 40s and men. The vast majority (~90%)

sis using two negative control outcomes, namely acute myocardial

lacked evidence of advanced liver disease. Before PS weighting

N=6,127 TDF Subjects
N=3,934 ETV Subjects

Minimum 1 year lookback period
Insurance Enrollment Start:

Censored time

Observation period

Observation Start:
First CHB Treatment
w/ TDF or ETV

Observation End
Earliest of
1. HCC claim
2. Liver transplant
3. Initiation of new CHB treatment
4. Insurance enrollment end
5. March 30, 2019 (data cutoff)

F I G U R E 1 Overall study scheme. A treatment-naïve chronic hepatitis B patient was identified by lack of anti-viral prescriptions for a
minimum of a year preceding the first prescription of ETV or TDF. The patient was then followed forward until one of the end points was
reached. Please note that liver transplantation and medication events including switching to a new anti-viral treatment were considered in
the analysis as competing events. CHB (chronic hepatitis B)

166,933 patients with evidence of HBV infection
(diagnosis or medication) and at least 1
year of prior enrollment
41

Unknown gender

4826

< 18 years at baseline

41,404

Co-infected with HCV, HDV, or HIV

108,555 No evidence of treatment with TDF or ETV,
or treatment with both TDF and ETV

F I G U R E 2 Patient disposition. A
total of 10 061 adult patients with HBV
monoinfection without any prior HBV
therapy or evidence of prevalent HCC
who were newly treated with ETV
(N = 3934) or TDF (N = 6127) were
included in the study

10,061

452

Any prior HBV-directed therapy (IFN,
adefovir, telbivudine, or lamivudine)

1594

Liver transplant, chemotherapy, or HCC
prior to or up to 6 mos after baseline

patients included in analysis

6127

TDF

3934

ETV

4
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TA B L E 1 Characteristics of patients with HBV infection receiving TDF and ETV, unweighted and inverse probability of treatment
weighted frequencies
n
Variable

Unweighted data

TDF (N = 6127)

ETV (N = 3934)

TDF %

ETV %

Weighted data
P

TDF %

ETV %

P

SMD (%)a

<0.01

11.3

11.2

1.00

2.5

0.63

1.0

Demographics
Age group (years)
18-29

845

299

13.8

7.6

30-39

1468

747

24.0

19.0

22.0

21.8

40-49

1684

1160

27.5

29.5

28.3

28.4

50-59

1391

1074

22.7

27.3

24.5

24.6

60-69

639

561

10.4

14.3

12.0

12.1

70+

100

93

1.6

2.4

1.9

1.9

2685

1441

43.8

36.6

<0.01

40.8

40.3

Cirrhosis/Fibrosis

487

384

8.0

9.8

<0.01

8.8

8.9

0.87

0.3

Portal hypertension

108

60

1.8

1.5

0.36

1.7

1.7

0.94

0.1

Ascites

Sex
Female
Liver disease at baseline

107

107

1.8

2.7

<0.01

2.1

2.1

0.98

0.0

Hepatic
encephalopathy

40

17

0.7

0.4

0.15

0.6

0.6

0.96

0.1

Bleeding oesophageal
varices

16

8

0.3

0.2

0.56

0.2

0.3

0.91

0.2

558

453

9.1

11.5

<0.01

10.0

10.4

0.54

0.2

Any liver disease at
baselineb
a

Standardised mean difference (<10% is considered well-balanced).

b

(left panel of Table 1), patients receiving TDF were more likely to
be younger (≤39 years) and female. The proportion with advanced
liver disease at baseline was higher among patients receiving ETV—
attributable to those with a diagnosis of cirrhosis/fibrosis and ascites. In contrast, hepatic encephalopathy and portal hypertension
tended to be more common among TDF-treated patients. After PS
weighting (right panel of Table 1), the two groups were well-balanced
in these variables.
The duration of follow-up was comparable between the two
treatment groups with a mean of 752 days and 791 days for ETV and

Cumuative incidence of HCC

Includes any of: cirrhosis/fibrosis, portal hypertension, ascites, hepatic encephalopathy and bleeding oesophageal varices (see ICD code listing in
Table S3).

0.10
0.08
0.06
0.04
0.02
0.00

0

1

TDF respectively. During the follow-up, a total of 2155 patients experienced competing risk events, including 13 liver transplantation
events, 405 anti-viral regimen changes and 1737 anti-viral treatment
breaks >90 days. A total of 90 patients developed HCC, including 40
patients receiving TDF and 50 receiving ETV, giving rise to a crude
HCC incidence rate of 0.62 per 100 person-years (95% CI: 0.46–0.81
per 100 person-years; total person-years = 8098) for ETV and 0.30

3
4
2
Person Years of Follow-Up
ETV

ETV 3934
TDF 6127

2443
3867

1440
2429

5

TDF
858
1506

507
955

327
653

F I G U R E 3 Occurrence of HCC. The incidence of HCC was
higher among patients receiving ETV than in those receiving TDF
(P < 0.01)

per 100 person-years (95% CI: 0.22–0.41 per 100 person-years;

account competing events as described above. Before adjustment or

total person-years = 13 261) for TDF (Figure 3).

weighting, TDF was associated with a reduction in risk of HCC (unad-

Table 2 summarises the results of the Fine-Gray regression anal-

justed sHR = 0.52, 95% CI: 0.34-0.79). The association of TDF with a

ysis using treatment as an exposure variable and including covariates

reduced risk of HCC relative to ETV persisted after adjustment in the

significant in the multivariable model at P < 0.10, while taking into

unweighted multivariable model (sHR = 0.58, 95% CI: 0.38-0.87).

|
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TA B L E 2 Risk of HCC associated
with TDF vs ETV: results of Fine-Gray
subdistribution hazards regression

Variable
TDF vs ETV

Univariatea

Multivariablea

Multivariable with IPTWa

HR (95% CI)

HR (95% CI)

HR (95% CI)

5

P

0.52 (0.34-0.79)

0.58 (0.38-0.87)

0.58 (0.38-0.89)

0.01

8.27 (1.10-62.14)

7.56 (1.01-56.53)

9.71 (1.03-91.52)

0.05

40–49

8.98 (1.22-66.35)

7.84 (1.07-57.26)

10.15 (1.10-94.19)

0.04

50–59

11.25 (1.53-83.08)

9.77 (1.34-71.50)

12.79 (1.38-118.71)

0.03

Age (reference 18–29)
30–39

60–69

22.10 (2.97-164.68) 18.50 (2.49-137.35)

25.49 (2.71-239.65)

< 0.01

70+

21.20 (2.20-204.21) 17.40 (1.82-166.75)

22.03 (1.80-269.20)

0.02

Sex (reference female)
Male
Portal hypertension

b

1.20 (0.78-1.84)

1.10 (0.71-1.69)

1.11 (0.72-1.73)

0.63

3.56 (1.32-9.64)

2.96 (1.06-8.25)

2.87 (1.04-7.94)

0.04

a

Univariate risk estimates are unadjusted for other risk factors; multivariable risk estimates are
mutually adjusted for all other presented risk factors; multivariable with IPTW risk estimates are
mutually adjusted and weighted with inverse probability of treatment weights.

b

Significant in the multivariable model at P < 0.10.

In the final IPTW-weighted, multivariable-adjusted model, TDF was

power, although given the nature of administrative claims data, only

associated with a statistically significant reduction in risk of HCC rel-

limited clinical data were available with which to characterise patient

ative to ETV (sHR = 0.58; 95% CI: 0.38-0.89, p = 0.01).

phenotypes.

Supplementary analyses were conducted to further assess the

Published studies on HBV treatment regimens and long-

validity of our analysis. In sensitivity analyses to assess whether

term outcomes of HCC to date have reported disparate results,

the results above were potentially influenced by the use of TDF in

making this one of the more debated topics in viral hepatitis

young, pregnant women, we repeated the multivariable weighted

research.7,21,23–29,31–3 3 These studies are predominantly derived

analyses limited to patients ≥40 years of age. The resulting sHR was

from Asia, where the high prevalence of HBV and the high burden

0.47 (95% CI: 0.29-0.75). We also repeated the analysis separately

of HCC generate large amounts of observational data to enable

for each sex. The sHR was slightly higher in men (sHR = 0.62, 95%

such studies. Clearly, prospective randomised trials yield stron-

CI: 0.36-1.06) and lower in women (sHR = 0.54, 95% CI: 0.27-1.08)

ger evidence than observational studies; however, a prospective

than in the combined analysis. A third sensitivity analysis was con-

randomised trial to address this topic is unlikely to be forthcom-

ducted using a narrower definition of HCC (codes 155.0 and C22.0

ing. For example, to demonstrate the difference in HCC incidence

only, n = 79), which yielded a consistent result (sHR = 0.60, 95% CI:

rates comparable to those observed in this study (0.3-0 .8 per

0.39–0.93).

100 person-years), a study would require thousands of patients

Finally, in consideration of potential unmeasured confounding

randomised and followed for several years. A case in point may

in our study, we analysed our cohorts with negative control out-

be our sex-s tratified analysis, in which the difference between

comes, namely, acute myocardial infarction (AMI) and emphysema

ETV and TDF lost statistical significance when the sample size

(Table S4). In univariate, unweighted multivariable, and weighted

decreased from 10 061 (combined total) to 4126 (women only)

multivariable analyses, TDF vs ETV had no impact on either negative

and 5935 (men only).

control outcome.

We designed this observational study to ensure its scientific
validity by maximising comparability between the two treatment

4 | D I S CU S S I O N

groups. First, prior Asian studies were affected by the significant
gap in approval dates for the two regimens throughout Asia which
resulted in imbalance in study subjects with regard to prior anti-viral

In this work, we utilised a large US administrative claims database to

exposure and proportions of advanced liver disease and cirrhosis.34

examine the impact of initiating therapy with two first-line anti-HBV

In the United States, the ETV and TDF FDA approval dates are much

agents, ETV and TDF, on future occurrence of HCC. After adjust-

closer together: ETV was approved in 2005 and TDF in 2008 for

ing for multiple covariates and applying PS weighting methods to

chronic hepatitis B, although “off-label” use of TDF was not uncom-

ensure comparability of the two treatment groups, TDF was associ-

mon for HBV-monoinfected patients since TDF was approved for

ated with a 42% lower risk of HCC compared to ETV. In contrast to

use in HIV-1 infection in 2001.35,36 In this study, the earliest baseline

prior reports, our work makes a unique contribution to the literature

date for patients included was 1 January 2007, owing to the require-

for being a Western study incorporating a sample which is gener-

ment of 12 months of look-back, which resulted in the similar dura-

alisable to a large section of the population with robust statistical

tion of follow up.

6
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Second, we employed PS weighting to address the potential ef-

race. For example, compared to nucleoside analogues such as ETV,

fects of baseline differences between the two groups. Before match-

nucleotide analogues including TDF have been shown to induce

ing, there were small yet statistically significant differences—in part

interferon λ3 better, which may augment the anti-viral effect and

due to the large sample size—in the demographic and clinical char-

possibly provide anti-tumour activity against HCC.14–17 It has been

acteristics between the subjects receiving TDF vs ETV. This was

reported in the HCV literature that non-A sian subjects had higher

driven by the larger proportion of younger and female patients in the

prevalence of IL-28B variant alleles associated with a lower inter-

former, which likely reflects the use of TDF during pregnancy. For

feron λ3 response.43,44 Unfortunately, the claims data used in this

that particular concern, in addition to propensity weighting, we con-

analysis did not include race of the subject, preventing us from being

ducted sensitivity analyses restricted to older patients and stratified

able to make a direct comparison between Asians and non-A sians in

for sex; results from these analyses were consistent with our overall

the study. However, a large proportion, if not the majority, of HBV

findings with hazards of HCC for TDF vs ETV being lower by 38%

patients in the US are of Asian ancestry.

(HR = 0.62, in men) to 53% (HR = 0.47, for age ≥40 years), statistical

We acknowledge further limitations for the study. First, adminis-

significance notwithstanding. Lastly, competing risk analyses were

trative claims data lack information that might provide more detailed

used to exclude potential impact of changes in the anti-viral regimen

biological or clinical insights. In addition to race and ethnicity, labo-

as well as other competing events such as liver transplantation.

ratory data such as histology, liver fibrosis, and serum ALT and viro-

Third, we focused on treatment-naïve patients by excluding indi-

logical features such as HBV DNA were not available. Due to lack

viduals receiving any HBV therapy at any point during the year prior

of granularity in the claims codes, the distinction between fibrosis,

to cohort entry, since choice of anti-viral regimens in patients who

cirrhosis and decompensated cirrhosis may not be made definitively.

have been exposed to multiple prior agents confound the current

Death, a potential competing risk for HCC, was not reliably captured.

fibrosis status and future HCC risk. This study design resulted in the

These limitations may have led to some misclassification between

low (~10%) proportion of patients with a diagnosis indicative of cir-

the two treatment groups; however, it is unlikely that this misclassi-

rhosis or advanced liver disease at baseline. Although it is likely that

fication is differential, which would, if anything, tend to bias results

cirrhosis is under-diagnosed and -reported in administrative data,

towards the null, contrary to the observed significant risk estimate.

our study results in treatment-naïve patients among predominantly

Second, a patient’s enrolment in US commercial health insurance

non-cirrhotic patients enrich the literature to date.

coverage may change over time, often because insurance is typically

Anti-viral therapy may reduce the incidence of HCC via at least

linked to employment; these short enrolment periods result in short

three mechanisms including (1) direct effects on inflammation in

follow-up periods within the data set. However, due to the study’s

response to viral activities, (2) impact on fibrosis regression, found

sample size, sufficient numbers of events were observed in order

after long-term (>5 years) therapy, and (3) possibly interference with

to detect an effect. Finally, it is possible that the observed results

integration of viral DNA into the host genome.

37

In our study, we

may have been influenced by unmeasured, residual confounding. We

observed a significant reduction in HCC incidence over a relatively

conducted two unrelated, negative control outcome analyses which

short term in patients without advanced fibrosis. We interpret this

suggest that such influences are unlikely to be responsible for the

to indicate that the risk reduction in our study may be driven by the

observed association of TDF with reduced risk of HCC.

direct effects on viral replication and liver inflammation. In contrast,

In summary, in this analysis of a large US administrative claims

for example, fibrosis regression would take much longer and there

database, we demonstrate that the incidence rate of HCC among

are no data to suggest differences in fibrosis regression between

chronic hepatitis B patients treated with TDF was lower than that

ETV-and TDF-treated patients.

among those with ETV. The difference held up after adjusting for

Although limited in number, studies from Europe and the United

demographic characteristics, baseline conditions and PS weight-

States to date have tended to report no difference in HCC incidence

ing. To the degree that our analysis was limited to treatment-naïve

between TDF-and ETV-treated patients. 26–29,31,38 In addition to the

patients, our data may not support altering treatment strategies in

timing of introduction of the agents,34 there may be biological dif-

patients who are doing well on an anti-v iral medication. In patients

ferences between Asian and non-A sian populations. First, although

who are being prescribed ETV or TDF for the first time, our find-

head-to-head comparisons are limited, prior data have indicated that

ings may be helpful when considering future risks of HCC. In pa-

TDF may provide more potent viral suppression than ETV,39 whereas

tients who are thought to be at a greater risk of HCC (eg HBeAg+,

incomplete viral control may eventually translate to higher carcino-

high serum HBV DNA, high serum ALT, male),45 any reduction (eg

genesis. Non-A sian patients tend to have lower serum HBV DNA,

11%-62%, complements of lower and upper bounds of the 95%

which may render TDF’s relative advantage over ETV less apparent

confidence interval shown in Table 2) in HCC risk may be mean-

than among Asians.40 Second, TDF has been associated with pres-

ingful. This difference, however, would be less pronounced among

ervation of telomere length which has been proposed as a potential

lower risk patients. In light of the increasing consensus among

41,42

Such an effect may be

published studies, at least among Asian patients, we propose that

expected to be more pronounced in younger patients, with whom

clinicians take into account this information for patients starting

Asian cohorts tend to be enriched. Finally, ETV and TDF may elicit

anti-v iral therapy who are considered to be at a heightened risk

innate immune responses differently and this effect may differ by

of HCC.

mechanism for protection against HCC.
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